Prostate cancer risk in men with prostate and breast cancer family history

Results from the REDUCE study (R1)

J. A. Thomas, L. Gerber, D. M. Moreira, R. J. Hamilton, L. L. Bañez, R. Castro-Santamaria, G. L. Andriole, William B Isaacs, J. Xu, S. J. Freedland

Research output: Contribution to journalArticle

Abstract

Background. To what degree the associations between PCa risk and family history of prostate cancer (PCa) and/or breast cancer (BCa) are attributable to screening biases is unclear. We examined these questions within the REDUCE study, where biopsies were largely independent of prostate specific antigen (PSA) minimizing screening biases. Methods. Data were from REDUCE, which tested dutasteride 0.5mg daily for PCa risk reduction in men with PSA 2.5-10.0ngmL -1 and a negative prestudy biopsy. Among men undergoing at least one on-study biopsy with complete data (n=6415; 78.1%), the association between family history and PCa risk was tested using multivariate logistic regression adjusting for clinicodemographic characteristics. Results. A family history of PCa alone was associated with increased PCa diagnosis (OR: 1.47, 95%CI: 1.22-1.77). In North America, PCa family history was not related to PCa diagnosis (OR: 1.02, 95%CI: 0.73-1.44), whereas outside North America, PCa family history was significantly related to diagnosis (OR: 1.72, 95%CI: 1.38-2.15) (P-interaction=0.01). A family history of both PCa and BCa (OR: 2.54, 95%CI: 1.72-3.75) but not BCa alone (OR: 1.04, 95%CI: 0.84-1.29) was associated with increased PCa risk versus no family history and irrespective of geographical region. Conclusions. In REDUCE, PCa family history was significantly related to PCa diagnosis, although only for men outside North America. The presence of both PCa and BCa family history significantly increased risk versus PCa family history alone, irrespective of geographical region. Ultimately, our observations may support the need for changes in how we address family history in terms of both risk of PCa diagnosis and general risk stratification.

Original languageEnglish (US)
Pages (from-to)85-92
Number of pages8
JournalJournal of Internal Medicine
Volume272
Issue number1
DOIs
StatePublished - Jul 2012

Fingerprint

Prostatic Neoplasms
Breast Neoplasms
North America
Prostate-Specific Antigen
Biopsy
Risk Reduction Behavior
Logistic Models

Keywords

  • Breast cancer
  • Family history
  • Prostate cancer
  • REDUCE

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Thomas, J. A., Gerber, L., Moreira, D. M., Hamilton, R. J., Bañez, L. L., Castro-Santamaria, R., ... Freedland, S. J. (2012). Prostate cancer risk in men with prostate and breast cancer family history: Results from the REDUCE study (R1). Journal of Internal Medicine, 272(1), 85-92. https://doi.org/10.1111/j.1365-2796.2011.02504.x

Prostate cancer risk in men with prostate and breast cancer family history : Results from the REDUCE study (R1). / Thomas, J. A.; Gerber, L.; Moreira, D. M.; Hamilton, R. J.; Bañez, L. L.; Castro-Santamaria, R.; Andriole, G. L.; Isaacs, William B; Xu, J.; Freedland, S. J.

In: Journal of Internal Medicine, Vol. 272, No. 1, 07.2012, p. 85-92.

Research output: Contribution to journalArticle

Thomas, JA, Gerber, L, Moreira, DM, Hamilton, RJ, Bañez, LL, Castro-Santamaria, R, Andriole, GL, Isaacs, WB, Xu, J & Freedland, SJ 2012, 'Prostate cancer risk in men with prostate and breast cancer family history: Results from the REDUCE study (R1)', Journal of Internal Medicine, vol. 272, no. 1, pp. 85-92. https://doi.org/10.1111/j.1365-2796.2011.02504.x
Thomas, J. A. ; Gerber, L. ; Moreira, D. M. ; Hamilton, R. J. ; Bañez, L. L. ; Castro-Santamaria, R. ; Andriole, G. L. ; Isaacs, William B ; Xu, J. ; Freedland, S. J. / Prostate cancer risk in men with prostate and breast cancer family history : Results from the REDUCE study (R1). In: Journal of Internal Medicine. 2012 ; Vol. 272, No. 1. pp. 85-92.
@article{f00d70b102194e998efafa8ca1266dbb,
title = "Prostate cancer risk in men with prostate and breast cancer family history: Results from the REDUCE study (R1)",
abstract = "Background. To what degree the associations between PCa risk and family history of prostate cancer (PCa) and/or breast cancer (BCa) are attributable to screening biases is unclear. We examined these questions within the REDUCE study, where biopsies were largely independent of prostate specific antigen (PSA) minimizing screening biases. Methods. Data were from REDUCE, which tested dutasteride 0.5mg daily for PCa risk reduction in men with PSA 2.5-10.0ngmL -1 and a negative prestudy biopsy. Among men undergoing at least one on-study biopsy with complete data (n=6415; 78.1{\%}), the association between family history and PCa risk was tested using multivariate logistic regression adjusting for clinicodemographic characteristics. Results. A family history of PCa alone was associated with increased PCa diagnosis (OR: 1.47, 95{\%}CI: 1.22-1.77). In North America, PCa family history was not related to PCa diagnosis (OR: 1.02, 95{\%}CI: 0.73-1.44), whereas outside North America, PCa family history was significantly related to diagnosis (OR: 1.72, 95{\%}CI: 1.38-2.15) (P-interaction=0.01). A family history of both PCa and BCa (OR: 2.54, 95{\%}CI: 1.72-3.75) but not BCa alone (OR: 1.04, 95{\%}CI: 0.84-1.29) was associated with increased PCa risk versus no family history and irrespective of geographical region. Conclusions. In REDUCE, PCa family history was significantly related to PCa diagnosis, although only for men outside North America. The presence of both PCa and BCa family history significantly increased risk versus PCa family history alone, irrespective of geographical region. Ultimately, our observations may support the need for changes in how we address family history in terms of both risk of PCa diagnosis and general risk stratification.",
keywords = "Breast cancer, Family history, Prostate cancer, REDUCE",
author = "Thomas, {J. A.} and L. Gerber and Moreira, {D. M.} and Hamilton, {R. J.} and Ba{\~n}ez, {L. L.} and R. Castro-Santamaria and Andriole, {G. L.} and Isaacs, {William B} and J. Xu and Freedland, {S. J.}",
year = "2012",
month = "7",
doi = "10.1111/j.1365-2796.2011.02504.x",
language = "English (US)",
volume = "272",
pages = "85--92",
journal = "Journal of Internal Medicine",
issn = "0954-6820",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Prostate cancer risk in men with prostate and breast cancer family history

T2 - Results from the REDUCE study (R1)

AU - Thomas, J. A.

AU - Gerber, L.

AU - Moreira, D. M.

AU - Hamilton, R. J.

AU - Bañez, L. L.

AU - Castro-Santamaria, R.

AU - Andriole, G. L.

AU - Isaacs, William B

AU - Xu, J.

AU - Freedland, S. J.

PY - 2012/7

Y1 - 2012/7

N2 - Background. To what degree the associations between PCa risk and family history of prostate cancer (PCa) and/or breast cancer (BCa) are attributable to screening biases is unclear. We examined these questions within the REDUCE study, where biopsies were largely independent of prostate specific antigen (PSA) minimizing screening biases. Methods. Data were from REDUCE, which tested dutasteride 0.5mg daily for PCa risk reduction in men with PSA 2.5-10.0ngmL -1 and a negative prestudy biopsy. Among men undergoing at least one on-study biopsy with complete data (n=6415; 78.1%), the association between family history and PCa risk was tested using multivariate logistic regression adjusting for clinicodemographic characteristics. Results. A family history of PCa alone was associated with increased PCa diagnosis (OR: 1.47, 95%CI: 1.22-1.77). In North America, PCa family history was not related to PCa diagnosis (OR: 1.02, 95%CI: 0.73-1.44), whereas outside North America, PCa family history was significantly related to diagnosis (OR: 1.72, 95%CI: 1.38-2.15) (P-interaction=0.01). A family history of both PCa and BCa (OR: 2.54, 95%CI: 1.72-3.75) but not BCa alone (OR: 1.04, 95%CI: 0.84-1.29) was associated with increased PCa risk versus no family history and irrespective of geographical region. Conclusions. In REDUCE, PCa family history was significantly related to PCa diagnosis, although only for men outside North America. The presence of both PCa and BCa family history significantly increased risk versus PCa family history alone, irrespective of geographical region. Ultimately, our observations may support the need for changes in how we address family history in terms of both risk of PCa diagnosis and general risk stratification.

AB - Background. To what degree the associations between PCa risk and family history of prostate cancer (PCa) and/or breast cancer (BCa) are attributable to screening biases is unclear. We examined these questions within the REDUCE study, where biopsies were largely independent of prostate specific antigen (PSA) minimizing screening biases. Methods. Data were from REDUCE, which tested dutasteride 0.5mg daily for PCa risk reduction in men with PSA 2.5-10.0ngmL -1 and a negative prestudy biopsy. Among men undergoing at least one on-study biopsy with complete data (n=6415; 78.1%), the association between family history and PCa risk was tested using multivariate logistic regression adjusting for clinicodemographic characteristics. Results. A family history of PCa alone was associated with increased PCa diagnosis (OR: 1.47, 95%CI: 1.22-1.77). In North America, PCa family history was not related to PCa diagnosis (OR: 1.02, 95%CI: 0.73-1.44), whereas outside North America, PCa family history was significantly related to diagnosis (OR: 1.72, 95%CI: 1.38-2.15) (P-interaction=0.01). A family history of both PCa and BCa (OR: 2.54, 95%CI: 1.72-3.75) but not BCa alone (OR: 1.04, 95%CI: 0.84-1.29) was associated with increased PCa risk versus no family history and irrespective of geographical region. Conclusions. In REDUCE, PCa family history was significantly related to PCa diagnosis, although only for men outside North America. The presence of both PCa and BCa family history significantly increased risk versus PCa family history alone, irrespective of geographical region. Ultimately, our observations may support the need for changes in how we address family history in terms of both risk of PCa diagnosis and general risk stratification.

KW - Breast cancer

KW - Family history

KW - Prostate cancer

KW - REDUCE

UR - http://www.scopus.com/inward/record.url?scp=84862781644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862781644&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2796.2011.02504.x

DO - 10.1111/j.1365-2796.2011.02504.x

M3 - Article

VL - 272

SP - 85

EP - 92

JO - Journal of Internal Medicine

JF - Journal of Internal Medicine

SN - 0954-6820

IS - 1

ER -